Literature DB >> 18057006

Vpr.A3A chimera inhibits HIV replication.

Renato S Aguiar1, Nika Lovsin, Amilcar Tanuri, B Matija Peterlin.   

Abstract

Several APOBEC3 proteins (A3F and A3G), that are cytidine deaminases restrict human immunodeficiency virus (HIV) replication in the absence of the viral infectivity factor (Vif) protein. However, Vif leads to their degradation and counteracts their effects. Another member, A3A, restricts some retrotransposons and another virus but not HIV. We reasoned that this failure was due to the lack of appropriate targeting. Thus, we fused A3A to another viral protein, Vpr, which binds p6 in Gag and is incorporated into viral cores. Indeed, the Vpr.A3A chimera but not A3A was found abundantly in the viral core. It also restricted potently the replication of HIV and simian immunodeficiency virus in the presence and absence of Vif. Because we identified a high frequency of G to A mutations in viral cDNAs, this antiviral activity was mediated by DNA editing. Interestingly, our fusion protein did not restrict murine leukemia virus, which does not incorporate Vpr. Thus, by targeting appropriately a potent single domain cytidine deaminase, we rendered HIV and simian immunodeficiency virus restriction resistant to Vif.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057006     DOI: 10.1074/jbc.M706436200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 3.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

4.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 5.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

6.  N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.

Authors:  Yudi Wang; Qiujia Shao; Xianghui Yu; Wei Kong; James E K Hildreth; Bindong Liu
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

7.  Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes.

Authors:  André Berger; Carsten Münk; Matthias Schweizer; Klaus Cichutek; Silke Schüle; Egbert Flory
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

8.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

9.  APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription.

Authors:  Alyssa L MacMillan; Rahul M Kohli; Susan R Ross
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  APOBEC3 proteins mediate the clearance of foreign DNA from human cells.

Authors:  Mark D Stenglein; Michael B Burns; Ming Li; Joy Lengyel; Reuben S Harris
Journal:  Nat Struct Mol Biol       Date:  2010-01-10       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.